High medical spending on prostate cancer screenings yields little benefit for men over 75

Prostate cancer is a big problem for the elder aged men. To help and treat it there is enhancement screening. According to the recent research conducted at the Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center proves that the screening lead to very little benefit for men aged 75 and the older ones.

The research was published in journal Cancer. Further deepening the study the researchers came out with the conclusion that they should not waste much money is spending prostate cancer. Rather they should rely on other medication.

A member of the team from Yale Cancer Center explains, “More than 70% of prostate cancer screening-related costs were due to follow-up procedures. Our results suggest that the overall cost of prostate cancer screening may be heavily influenced by how urologists choose to respond to the result of a PSA test, more so than the use of the PSA itself.”